The Efficacy and Safety of Regorafenib Plus PD-1 Inhibitor as Third-line Therapy in Advanced Colorectal Cancer Patients
Latest Information Update: 06 Dec 2022
At a glance
- Drugs Nivolumab (Primary) ; Regorafenib (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- 29 Dec 2020 Planned primary completion date changed from 31 Aug 2020 to 31 Aug 2021.
- 07 Oct 2019 Planned number of patients changed from 40 to 120.
- 04 Oct 2019 New trial record